Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil

  • Maricea Engel1,
  • Fernanda M Malta1,
  • Michele MS Gomes1,
  • Isabel MVGC Mello1,
  • João RR Pinho1,
  • Suzane K Ono-Nita1 and
  • Flair J Carrilho1Email author
BMC Public Health20077:50

DOI: 10.1186/1471-2458-7-50

Received: 28 August 2006

Accepted: 04 April 2007

Published: 04 April 2007

Abstract

Background

Chronic hemodialysis patients are at higher risk for acquiring hepatitis C virus (HCV). The prevalence varies among different countries and hemodialysis centers. Although guidelines for a comprehensive infection control program exist, the nosocomial transmission still accounts for the new cases of infection. The aim of this study was analyze the follow up of newly acquired acute hepatitis C cases, during the period from January 2002 to May 2005, in the Hemodialysis Center, located in the Southwest region of Parana State, Brazil and to analyze the effectiveness of the measures to restrain the appearance of new cases of acute hepatitis C.

Methods

Patients were analyzed monthly with anti-HCV tests and ALT measurements. Patients with ALT elevations were monitored for possible acute hepatitis C.

Results

During this period, 32 new cases were identified with acute hepatitis C virus infection. Blood screening showed variable ALT levels preceding the anti-HCV seroconversion. HCV RNA viremia by PCR analysis was intermittently and even negative in some cases. Ten out of 32 patients received 1 mcg/kg dose of pegylated interferon alfa-2b treatment for 24 weeks. All dialysis personnel were re-trained to strictly follow the regulations and recommendations regarding infection control, proper methods to clean and disinfect equipment were reviewed and HCV-positive patients were isolated.

Conclusion

Laboratory tests results showed variable ALT preceding anti-HCV seroconversion and intermittent viremia. The applied recommendations contributed importantly to restrain the appearance of new cases of acute hepatitis C in this center and the last case was diagnosed in May 2004.

Background

Hepatitis C virus (HCV) prevalence differs among hemodialysis units according to their geographical location, health care procedures, socioeconomic factors, reuse of lines, hygiene and sterilization of equipment, patient rotation of machines and the undertaking of rigorous universal precaution rules. These features influence the risk of nosocomial transmission of HCV to hemodialysis patients [13]. Previous reports reinforces the importance of vigilance in these units [2, 4, 5], especially the strict following of recommendations to prevent the transmission of infectious diseases among these patients [6].

In chronic renal patients, hepatitis C virus infection is often difficult to evaluate. The results of assays used to diagnose this infection can be hard to interpret due to the particular features found in this population. The identification of acute HCV infection cases can be influenced by several factors: a) absence of symptoms in acute cases, the majority of them without jaundice and with symptoms related to the base of the disease or to chronic anemia; b) slight increases of aminotransferases levels; C) anti-HCV negative serology or positive after several months of contamination; and d) intermittent viremia. Patients presenting intermittent viremia were described in 33% to 67% of anti-HCV positive patients [79]. The levels of alanins aminotransferase (ALT) are generally lower in patients with renal failure. Previous reports shown the need to establish lower ALT levels standard to increase the accuracy of this assay in detecting liver diseases [1012].

The aims of this study were to follow the development of acute hepatitis C cases in a renal therapy unit located in the southeast of Parana from January 2002 to May 2005, and the response to the measures taken to avoid new acute hepatitis C cases.

Methods

Study design

From January 2002 to May 2005, we prospectively followed up all patients at a single hemodialysis unit in Pato Branco city, southeast Parana, Brazil. The study patients were prospectively tested every month by a third-generation anti-HCV ELISA. Positive results obtained by ELISA test were confirmed by HCV RNA testing. ALT determination in the study group was performed each month.

Determination of HCV RNA and HCV genotype

Serum HCV RNA was detected as follows: RNA was extracted from 100 micro liters of serum by guanidinium isothiocyanate, phenol chloroform extraction described by Chomczynski & Sacchi [13]. Complementary DNA was synthesized using random primers and reverse transcriptase Moloney Murine Leukemia Virus (M-MLV) (Invitrogen Life Technologies, Carlsbad, CA, USA). HCV RNA was detected by two-stage polymerase chain reaction (PCR) using primers from the 5' – untranslated region of the HCV genome, as previously described [14]. HCV genotypes of the patients with HCV viremia were determined by sequencing (Applied Biosystems, Foster city, CA, USA), as previously described [14].

IFN therapy and follow-up

Infected patients were informed of the possible risks and benefits of IFN treatment. Ten out 32 patients diagnosed with acute hepatitis C were treated with pegylated interferon 1 mcg/kg/weekly for 24 weeks. Pegylated IFN-a 2b (Intron A; Schering-Plough Corp., Kenilworth, NJ) was patient-administered subcutaneously at doses of 1 microgram/kg/weekly for 24 weeks. Each patient check-up included measurement of serum ALT levels and a complete blood count, and this was done in the outpatient clinic at 1-week intervals during the first month, at 2-week intervals during the second and third months of treatment, and monthly after the end of the treatment. Serum HCV RNA was assessed qualitatively before treatment, at end of treatment and at month 6 post-treatment. Sustained virological response was considered in cases with undetectable HCV RNA 6 months after the end of treatment.

All patients gave written informed consent. The study was approved by the local hospital ethical committee and Clinical Hospital of the University of São Paulo School of Medicine.

Infection control training and education

After the detection of new acute hepatitis C cases, more stringent precautions were taken at the hemodialysis units to reduce the appearance of new cases.

The measures were based on different publications and recommendations [3, 6, 1517] and in brief are summarized as follows:

a) Reeducation of existing staff members regarding Recommended Infection Control Practices for Hemodialysis.

b) All the equipment used on patients with positive serology, such as stethoscope, sphygmomanometer, and Micropore dressings were separated. Isolated carts were installed for use according to anti-HCV serology.

c) Patients attending the unit who had been transferred from another centre and with ALT alterations were isolated until serological confirmation.

d) As in 2002 new cases continued to arise, it was decided to separate patients with anti-HCV positive to undergo dialysis sessions on Mondays, Wednesdays and Fridays, while the anti-HCV negative patients to Tuesdays, Thursdays and Saturdays, always utilizing the same machine for each patient. The transportation of patients was separated in accordance to HCV serology or HCV-RNA because of the possibility of episodes of vascular bleeding (fistula) due to heparinization.

e) Hemodialysis machines were sterilized after each session of dialysis with Persteril 3.5 [peracetic acid 3.5%] and externally cleaned with soap and water. There were also changes in the sterilizing procedures of the lines (reuse). The lines were sterilized in separate rooms, conforming to serology (anti-HCV positive, anti-HCV negative HBsAg positive), in semi-automatic reprocessing device for up to 10 lines, to sterilizing the lines of patients with anti-HCV negative serology in individual automatic reprocessing device (Renatron, Minntech Renal Systems) with hydrogen peroxide 20%, peracetic acid 4.5%. The lines were reused in accordance with the internal number of them (priming), being discarded with priming < 80% or depending on its reuse, no more than 12 times when reprocessed manually, or up to 20 times when reprocessed automatically, in agreement with the resolution – RDC # 154, 15th of July 2004 [18].

f) The health-care workers from the unit were examined for anti-HCV (12 nursing technicians, 2 nurses, 2 nephrology doctors and 2 maintenance workers) and were all serologically negative.

Results

Table 1 shows the number of patients followed at the hemodialysis unit. We identified by anti-HCV ELISA 32 patients with acute HCV infection over the study period. A higher number of cases at the initial stages of the studies were diagnosed and their number decreased over the subsequent years (Table 2).
Table 1

Number of patients followed at the hemodialysis center and acute hepatitis C new cases

 

2002

2003

2004

May/2005

Initial total number of patients

74

86

87

71

Admissions

40

32

37

21

Deaths

12

15

18

04

Drop-outs

13

09

16

09

Kidney transplantations

03

07

19

03

Total number of patients

86

87

71

76

Total acute hepatits C new cases

20

06

06

00

Table 2

ALT levels 4 months before anti-HCV seroconversion from patients followed up from January 2002 to May 2005

Case number

ALT levels 4 months before seroconversion

ALT/Anti-HCV seroconversion month

01

17

12

28

223

20/March 2002

02

10

28

325

253

179/March 2002

03

27

162

248

13

19/April 2002

04

16

21

76

250

15/May 2002

05

26

34

26

63

280/May 2002

06

12

11

57

179

56/May 2002

07

14

13

17

22

19/May 2002

08

24

19

34

33

63/May 2002

09

22

52

73

164

178/May 2002

10

18

35

85

270

26/May 2002

11

03

25

18

78

179/July 2002

12

25

14

143

111

203/July 2002

13

04

05

15

250

318/July 2002

14

15

26

13

226

31/August 2002

15

11

04

25

253

187/August 2002

16

61

69

201

61

190/September 2002

17

07

22

29

246

159/September 2002

18

16

29

84

102

73/September 2002

19

66

17

18

45

124/September 2002

20

25

37

30

105

275/November 2002

21

26

39

183

100

304/January 2003

22

05

07

38

174

110/January 2003

23

04

14

50

111

18/January 2003

24

37

40

39

28

114/January 2003

25

14

69

318

158

99/November 2003

26

11

38

31

85

52/November 2003

27

08

24

186

36

08/January 2004

28

12

51

114

195

223/January 2004

29

14

08

12

94

-/February 2004

30

26

28

41

33

203/March 2004

31

-

-

14

24

103/April 2004

32

07

11

63

54

54/May 2004

Ten patients were selected for treatment. We used pegylated interferon alfa 2b, at dose of 1 mcg/Kg body weight, during 24 weeks. The selected patients could not be standardized in relation to the onset of the disease. Patients started treatment an average 6.9 ± 3.5 months after the first HCV was positive. Of the 10 patients treated, four (cases 14, 16, 23, 32) had sustained virological response, three (cases 15, 19, 24) did not responded to treatment, one patient (case 31) died during treatment, owing to fistula infection and pneumonia, without evidence of leukopenia. One patient (case 27) with a high ALT level and anti-HCV seroconversion received treatment and was HCV-RNA negative in the samples collected thereafter. Another patient (case 25), from whom samples of HCV-RNA were taken 3 months prior to treatment, did not showed a positive PCR, therefore we could not determine if these two cases responses were due to natural causes or therapeutic response.

At the end of the investigation, among the 32 cases with acute HCV infection, 12 patients had detectable PCR-RNA (one case treated), 10 had PCR-RNA not detected (six treated), nine deaths (three treated) and the loss of one case report (hemodialysis unit changed)

HCVgenotyping showed 22 cases infected with type 1 three cases with type 3 (Table 3). In seven cases, it was not possible to carry out the genotyping because of negative HCV RNA at the samples.
Table 3

HCV genotype from the 32 cases of acute HCV

Genotype

Total

1

22

3

3

Not done

7

Total

32

Liver biopsy was carried out on just three patients, without adverse events, all presenting slight histological alterations according to the Brazilian Society of Pathology classification. A histological study was not carried out on the other patients. After the detection of new acute hepatitis C virus cases and their treatment, measures were taken to restrain other detected outbreaks and reduce the appearance of new cases.

The measures established were based on different publications and recommendations by the National Agency of Sanitary Vigilance [18, 3, 6, 1517] and followed as described above in the Material and Methods section.

As in 2002 new cases continued to arise, it was decided to separate patients with anti-HCV positive to undergo dialysis sessions on Mondays, Wednesdays and Fridays, while the anti-HCV negative patients to Tuesdays, Thursdays and Saturdays, always utilizing the same machine for each patient.

With the measures established the hepatitis C outbreak was controlled and last case of acute hepatitis C seen in this unit was May 2004.

Discussion

Nosocomial transmission of the HCV in dialysis units is not a rare event observed world wide. However, the detection of acute HCV infection continues to be a challenge among this population.

The present study of haemodialysis patients lasted for 41 months and showed a high incidence of new hepatitis C cases over a short period, characterizing an outbreak of HCV infection in this unit.

During the investigation (January 2002 to May 2005), 32 new cases of acute hepatitis C were diagnosed. The detection of acute HCV infection was carried out through monthly ALT and anti-HCV markers observation. ALT elevations at the initial stages of HCV infection varied among patients, reaching a maximum of 325 IU/L, preceding up to 4 months the appearance of anti-HCV in the serum. It should be noted that the antibody in hemodialysis patients makes slower appearance than in non-hemodialysis patients and seroconversion may depend on each patient response. Therefore HCV RNA screening would be advisable, but a cost-effective analysis should be considered in this situation. To rule out false-positive ELISA in patients tested negative for HCV RNA, the immunoblot assay is still useful as a supplemental assay [19]. However, this is sometimes not available everywhere due to costs of the method.

The baseline levels of ALT in patients on dialysis are much lower than that of the general population. The study by Guh et al [10], suggests that the cutoff for the detection of HCV infection should be 16 UI/I for ALT and 18UI/I for aspartate transaminase (AST). Gouveia et al [20], suggest that higher normal limits of ALT should be reduced to 60% of conventional limits, when evaluating renal failure patients on dialysis. These lower levels are not yet fully accepted. Our results confirm the importance of monthly surveillance of ALT and that in even mild increases of the monthly standard can indicate acute HCV infection.

The confirmation of acute HCV infection is made by the detection of viremia. In our study confirmation was made by the detection of HCV-RNA using the Polymerase Chain Reaction (PCR). PCR is a good diagnostic test of HCV infection in chronic renal patients, despite observing variations in up to two thirds of patients possibly related to PCR inhibitors, that could be more frequent in patients on dialysis [21]. If positive, it suggests the presence of infection and makes possible the evaluation of the genotype. Another difficulty of this exam is that it is carried out in specialized laboratories prepared for molecular biology studies. Besides the technical characteristics of this method, another problem related to the intermittent viremia in these patients, is the need to carry out the exams repeatedly, representing a technical limitation and increasing costs.

Acute HCV infection cases, with confirmed viremia and without viral clearance up after 12 weeks, should be carefully evaluated for treatment, thus reducing the risks of the patients becoming chronic, which could worsen life expectancy, as in the response to renal transplantation.

Many investigators recommend interferon treatment for 24 weeks [22, 23]. Use of Ribavirin is not indicated in these patients because of the risk of hemolytic anemia [24, 25]. Pegylated interferon alfa 2b is excreted by the kidneys, therefore we used a lower dose (1 mcg per Kg) [26]. In our study, the selected patients could not be standardized in relation to the onset of the disease. Of the 10 treated patients, four had sustained virological response, three did not responded to treatment, one died during treatment, owing to fistula infection and pneumonia, however without evidence of leukopenia. One patient [27] with high ALT and seroconversion anti-HCV, received treatment, and had all collected samples clear of HCV-RNA. Another patient [25], whose samples of pre-treatment HCV-RNA were collected 3 months prior to treatment, developed non-detectable PCR, however, these cases cannot confirmed if it was due to therapeutic response or natural causes.

In the light of a HCV infection outbreak seen in our haemodialysis unit, we adopted concomitant measures for its identification, as well as the containment of new cases appearing. These measures included the retraining of personnel in relation to universal biosafety guidelines and universal precautions [6] and the importance of the health-care workers and controls in the nosocomial transmission. The patients were isolated in turns with positive serology for anti-HCV, this separation was also done while patients were in transfer because of possible vascular bleeding due to heparinization during dialysis [27]. All equipment utilized on patients was also separated. The procedure for sterilizing the dialysis machines was revised; the reprocessing device was modified using automatic and individual reprocessing in cases of negative serology.

In the haemodialysis units, the risk of infection has been related to the patients and units, characterizing nosocomial transmission [2, 28].

Pinto dos Santos et al [3] suggest that HCV transmission in haemodialysis units can be reduced by isolation of HCV positive patients, using separate machines and isolating the reused lines. As well as these investigators we observed the reduction of new cases after the isolation of cases in specific shifts. On the other hand, Jadoul et al [15] reinforce that only the following of universal rules and precautions would be enough to prevent transmission of HCV in haemodialysis units, without the need to isolate infected patients.

The effectiveness of isolation measures to prevent HCV infections is controversial. The strict observance of universal precautions has been sufficient to prevent nosocomial transmission of HCV. However, when selective isolation measures, such as, separation of equipment and patients, in a specific area of the unit, have been adopted, specially in units of high prevalence of HCV and also when the patient/health-care worker ratio is low, this involuntary favors the breach of universal precautions [1, 28]. Despite some controversy, in our case, the measures established were fundamental for the containment of the hepatitis C outbreak, the last case being registered 12 months from the end of the study.

Conclusion

It can be concluded that nosocomial transmission continues to have a major role in the transmission of HCV in haemodialysis units, that acute HCV infection be monitored and measures established to control the outbreak of new cases, and those cases with persistent viremia after 12 months, should be included in treatment procedures.

Abbreviations

HCV: 

hepatitis C virus

ALT: 

alanine aminotransferase

PCR: 

Polymerase Chain reaction

IFN: 

interferon

Declarations

Acknowledgements

We acknowledge Alves de Queiróz Family Fund for Research, Brazil for supporting this study.

Authors’ Affiliations

(1)
Department of Gastroenterology, Hepatology Branch, University of São Paulo, School of Medicine

References

  1. Barril G, Traver JA: Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures. Antiviral Res. 2003, 60 (2): 129-134. 10.1016/j.antiviral.2003.08.008.View ArticlePubMedGoogle Scholar
  2. McLaughlin KJ, Cameron SO, Good T, McCruden E, Ferguson JC, Davidson F, Simmonds P, Mactier RA, McMillan MA: Nosocomial transmission of hepatitis C virus within a British dialysis centre. Nephrol Dial Transplant. 1997, 12 (2): 304-309. 10.1093/ndt/12.2.304.View ArticlePubMedGoogle Scholar
  3. dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ: Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant. 1996, 11 (10): 2017-2022.View ArticlePubMedGoogle Scholar
  4. Castell J, Gutierrez G: [Outbreak of 18 cases of hepatitis C in a hemodialysis unit]. Gac Sanit. 2005, 19 (3): 214-220. 10.1157/13075954.View ArticlePubMedGoogle Scholar
  5. Delarocque-Astagneau E, Baffoy N, Thiers V, Simon N, de Valk H, Laperche S, Courouce AM, Astagneau P, Buisson C, Desenclos JC: Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine?. Infect Control Hosp Epidemiol. 2002, 23 (6): 328-334. 10.1086/502060.View ArticlePubMedGoogle Scholar
  6. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001, 50 (RR-5): 1-43.
  7. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Vinson S, Mousa M, Gitnick G: Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis. 2000, 35 (1): 122-129.View ArticlePubMedGoogle Scholar
  8. Fabrizi F, Bunnapradist S, Lunghi G, Martin P: Kinetics of hepatitis C virus load during hemodialysis: novel perspectives. J Nephrol. 2003, 16 (4): 467-475.PubMedGoogle Scholar
  9. Galan F, Perez-Gracia MT, Lozano A, Benavides B, Fernandez-Ruiz E, Rodriguez-Iglesias MA: A 3-year follow-up of HCV-RNA viraemia in haemodialysis patients. Nephrol Dial Transplant. 1998, 13 (5): 1211-1214. 10.1093/ndt/13.5.1211.View ArticlePubMedGoogle Scholar
  10. Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, Chen HC, Chang WY, Tsai JH: Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron. 1995, 69 (4): 459-465.View ArticlePubMedGoogle Scholar
  11. Saab S, Martin P, Brezina M, Gitnick G, Yee HF: Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis. Am J Kidney Dis. 2001, 37 (2): 308-315.View ArticlePubMedGoogle Scholar
  12. Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, Yokozeki K, Kobayashi S, Irie Y: Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology. 1995, 109 (4): 1295-1300. 10.1016/0016-5085(95)90591-X.View ArticlePubMedGoogle Scholar
  13. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162 (1): 156-159. 10.1016/0003-2697(87)90021-2.View ArticlePubMedGoogle Scholar
  14. Campiotto S, Pinho JR, Carrilho FJ, Da Silva LC, Souto FJ, Spinelli V, Pereira LM, Coelho HS, Silva AO, Fonseca JC, Rosa H, Lacet CM, Bernardini AP: Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res. 2005, 38 (1): 41-49. 10.1590/S0100-879X2005000100007.View ArticlePubMedGoogle Scholar
  15. Jadoul M, Cornu C, van Ypersele de Strihou C: Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int. 1998, 53 (4): 1022-1025. 10.1111/j.1523-1755.1998.00823.x.View ArticlePubMedGoogle Scholar
  16. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, Puro V, Casalino C, Ippolito G: Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001, 37 (5): 1004-1010.View ArticlePubMedGoogle Scholar
  17. Tokars JI, Miller ER, Alter MJ, Arduino MJ: National surveillance of dialysis associated diseases in the United States, 1995. Asaio J. 1998, 44 (1): 98-107. 10.1097/00002480-199801000-00019.View ArticlePubMedGoogle Scholar
  18. Agência Nacional de Vigilância Sanitária - ANVISA: Estabelece o Regulamento Técnico para o Funcionamento dos Serviços de Diálise. 2004, D.O.U. - Diário Oficial da União, 154:Google Scholar
  19. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology. 2002, 36 (5 Suppl 1): S3-20.
  20. Gouveia EC, Lopes EP, Moura I, Cruz M, Kosminsky L, Pernambuco JR: [Identification of the cutoff value for serum alanine aminotransferase in hepatitis C screening of patients with chronic renal failure on hemodialysis]. Rev Soc Bras Med Trop. 2004, 37 (1): 18-21.View ArticlePubMedGoogle Scholar
  21. Pol S, Vallet-Pichard A, Fontaine H, Lebray P: HCV infection and hemodialysis. Semin Nephrol. 2002, 22 (4): 331-339.PubMedGoogle Scholar
  22. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S: Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat. 2001, 8 (1): 70-77. 10.1046/j.1365-2893.2001.00268.x.View ArticlePubMedGoogle Scholar
  23. Urbanek P, Tesar V, Prochazkova-Francisci E, Lachmanova J, Marecek Z, Svobodnik A: Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. Blood Purif. 2004, 22 (4): 344-350. 10.1159/000079871.View ArticlePubMedGoogle Scholar
  24. Espinosa M, Rodriguez M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Lopez-Rubio F, de la Mata M, Aljama P: Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol. 2001, 55 (3): 220-226.PubMedGoogle Scholar
  25. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, Ishibashi H, Kashiwagi S: Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004, 39 (5): 1213-1219. 10.1002/hep.20196.View ArticlePubMedGoogle Scholar
  26. Foster GR: Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004, 20 (8): 825-830. 10.1111/j.1365-2036.2004.02170.x.View ArticlePubMedGoogle Scholar
  27. Yang CS, Chang HH, Chou CC, Peng SJ: Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit. J Formos Med Assoc. 2003, 102 (2): 79-85.PubMedGoogle Scholar
  28. Pujol FH, Ponce JG, Lema MG, Capriles F, Devesa M, Sirit F, Salazar M, Vasquez G, Monsalve F, Blitz-Dorfman L: High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J Clin Microbiol. 1996, 34 (7): 1633-1636.PubMedPubMed CentralGoogle Scholar
  29. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/7/50/prepub

Copyright

© Engel et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement